Transderm scop and Visual impairment - a phase IV clinical study of FDA data

Summary:

Visual impairment is reported as a side effect among people who take Transderm scop (scopolamine), especially for people who are female, 40-49 old, have been taking the drug for < 1 month also take Zofran, and have Nausea.

The phase IV clinical study analyzes which people have Visual impairment when taking Transderm scop. It is created by eHealthMe based on reports of 2,949 people who have side effects when taking Transderm scop from the FDA, and is updated regularly.

What is Transderm scop?

Transderm scop has active ingredients of scopolamine. It is often used in motion sickness. eHealthMe is studying from 3,011 Transderm scop users. Check the latest studies of Transderm scop.

What is Visual impairment?

Visual impairment is found to be associated with 2,249 drugs and 2,336 conditions by eHealthMe. Check the latest studies of Visual impairment.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 03, 2026

2,949 people reported to have side effects when taking Transderm scop.
Among them, 39 people (1.32%) have Visual impairment.

Could Transderm scop cause Visual impairment?

Among these 39 people:

How long have people been on Transderm scop when they have Visual impairment? *

What is the gender of people who have Visual impairment when taking Transderm scop? *

female: 78.38 %
male: 21.62 %

What is the age of people who have Visual impairment when taking Transderm scop? *

What are other drugs people take besides Transderm scop? *

What are other side effects people have besides Visual impairment? *

Vision Blurred: 17 people, 43.59%
Mydriasis (a dilation of the pupil): 14 people, 35.90%
Nausea (feeling of having an urge to vomit): 6 people, 15.38%
Dry Mouth: 5 people, 12.82%
Stress And Anxiety: 4 people, 10.26%
Headache (pain in head): 4 people, 10.26%
Adverse Drug Reaction: 4 people, 10.26%
Migraine (headache): 4 people, 10.26%
Oedema Peripheral (superficial swelling): 3 people, 7.69%
Balance Disorder: 3 people, 7.69%

What are the existing conditions these people have? *

Nausea (feeling of having an urge to vomit): 7 people, 17.95%
Narcolepsy (brain's inability to regulate sleep-wake cycles normally): 3 people, 7.69%
Procedural Nausea: 2 people, 5.13%
Constipation: 1 person, 2.56%
Diabetes: 1 person, 2.56%
High Blood Pressure: 1 person, 2.56%
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 1 person, 2.56%
Joint Pain: 1 person, 2.56%
Metastatic Renal Cell Carcinoma (spreadable kidney cell tumour): 1 person, 2.56%
Weight Decreased: 1 person, 2.56%

* Approximation only. Some reports may have incomplete information.

Do you take Transderm scop and have Visual impairment?

- Check whether Visual impairment is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Transderm scop:

Transderm scop (3,011 reports)

Visual impairment treatments and more:

Visual impairment (128,338 reports)

Browse all side effects of Transderm scop:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Visual impairment:

Visual impairment (2,249 drugs)

Browse all the conditions that are associated with Visual impairment:

Visual impairment (2,336 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on scopolamine (the active ingredients of Transderm scop) and Transderm scop (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.